DBV Technologies S.A.
DBV Technologies S.A. is a biotechnology company focused on the discovery, development, and commercialization of treatments for food allergies.
Stock Performance Snapshot
Financial Health
DBV Technologies is generating modest revenue and cash flow, but its financial position needs improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring DBVT
The Post-Pandemic Pediatric Pivot
The FDA's potential withdrawal of Pfizer's COVID vaccine for young children is reshaping the pediatric pharmaceutical landscape. This regulatory shift could create a significant market opening for other drugmakers focused on pediatric vaccines and therapies.
Published: August 13, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage pipeline
DBV’s patch approach targets a clear clinical need in food allergy treatment; clinical results will be a major driver, though trial outcomes can be binary.
Regulatory sensitivity
Regulatory feedback and approvals are pivotal; positive decisions can boost prospects while setbacks can weigh heavily on valuation.
Allergy market potential
Food allergies are a growing public‑health concern, which may offer long‑term opportunity, but commercial success is not guaranteed and depends on adoption.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Eli Lilly and Company
Eli Lilly & Co is a global pharmaceutical company that develops, manufactures and markets human prescription drugs.
Johnson & Johnson
Johnson & Johnson is a multinational conglomerate pharmaceutical, medical devices, and consumer packaged goods company.
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
